Paclitaxel Poliglumex (OPAXIO(TM))/Capecitabine Regimen Well Tolerated And Active In
At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (OPAXIO(TM), CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC). The goals of the study were to explore the tolerability and objective anti-tumor response rate as well as the disease-free progression and survival times of the regimen.
More... |
All times are GMT -7. The time now is 06:59 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021